Large clinical trials demonstrated that high amounts of IL-6 found in sera of advanced kidney, breast, and hepatocellular carcinoma, non-small cell lung cancer and bladder cancer patients correlate with poor response to the anti-PD-L1 antibody atezolizumab (101, 168–170). The gene discussed is IL6; the disease is urinary bladder carcinoma.